Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Zamubafusp Biologics Sequence Review Report 2026: Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope) Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zamubafusp, an antibody targeting Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope).
Read →
Latest Hotspot
8 min read
Zadoprubart Biologics Sequence Review Report 2026: BTLA Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zadoprubart, an antibody targeting BTLA.
Read →
Latest Hotspot
8 min read
Trevotamig Biologics Sequence Review Report 2026: EPCAM × CD3E Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trevotamig, an antibody targeting EPCAM × CD3E.
Read →
Latest Hotspot
8 min read
Remzistotug Biologics Sequence Review Report 2026: PVRIG Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Remzistotug, an antibody targeting PVRIG.
Read →
Latest Hotspot
8 min read
Produvofusp Biologics Sequence Review Report 2026: TBC Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Produvofusp, an antibody targeting TBC.
Read →
Latest Hotspot
8 min read
Nivisnebart Biologics Sequence Review Report 2026: SORT1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nivisnebart, an antibody targeting SORT1.
Read →
Latest Hotspot
8 min read
Lunlekitug Biologics Sequence Review Report 2026: IL1A Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lunlekitug, an antibody targeting IL1A.
Read →
Latest Hotspot
8 min read
Lotivibart Biologics Sequence Review Report 2026: HIV-1 gp120 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lotivibart, an antibody targeting HIV-1 gp120.
Read →
Latest Hotspot
8 min read
Lofacimig Biologics Sequence Review Report 2026: F11 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lofacimig, an antibody targeting F11.
Read →
Latest Hotspot
8 min read
Itanistomig Biologics Sequence Review Report 2026: PD-L1 × IAP Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Itanistomig, an antibody targeting PD-L1 × IAP.
Read →
Latest Hotspot
8 min read
Indematug Biologics Sequence Review Report 2026: IFNG Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Indematug, an antibody targeting IFNG.
Read →
Latest Hotspot
8 min read
Imeroprubart Biologics Sequence Review Report 2026: FCGRT Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imeroprubart, an antibody targeting FCGRT.
Read →
<
1
<<
424
425
426
427
428
>>
1503
>